• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how weโ€™re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCEยฎ
    • BRINSUPRIยฎ
  • Responsibility

    Responsibility

    See how weโ€™re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility in Action

    Our commitment to responsibility reflects the culture and purpose we live by every day.

    Visit our Responsibility site

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCEยฎ
      BRINSUPRIยฎ
  • Responsibility
    • Responsibility
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

Press Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Oct 17, 2005
    Insmed Submits Response to FDA Approvable Letter for iPlex

    Read more

  • Sep 29, 2005
    Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release

    Read more

  • Sep 29, 2005
    Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency

    Read more

  • Sep 25, 2005
    Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST

    Read more

  • Sep 24, 2005
    Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director

    Read more

  • Sep 19, 2005
    SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France

    Read more

  • Aug 8, 2005
    Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005

    Read more

  • Aug 2, 2005
    Insmed to Release Second Quarter Financial Results; Monday, August 8

    Read more

  • Jun 10, 2005
    FDA Extends PDUFA Date for SomatoKine to October 03, 2005

    Read more

  • May 31, 2005
    Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome

    Read more

  • May 25, 2005
    Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005

    Read more

  • May 24, 2005
    Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica

    Read more

  • May 19, 2005
    Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005

    Read more

  • May 17, 2005
    Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer

    Read more

  • May 10, 2005
    Insmed Incorporated Reports Financial Results for First Quarter of 2005

    Read more

  • May 5, 2005
    Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)

    Read more

  • Apr 26, 2005
    Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance

    Read more

  • Apr 20, 2005
    Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)

    Read more

  • Apr 18, 2005
    Patent Infringement Suit Against Insmed Dismissed

    Read more

  • Apr 13, 2005
    FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

    Read more

  • Mar 16, 2005
    Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004

    Read more

  • Mar 15, 2005
    Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16

    Read more

  • Mar 15, 2005
    Insmed Announces Completion of $35 Million Financing

    Read more

  • Mar 10, 2005
    FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

    Read more

  • Feb 22, 2005
    Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims

    Read more

  • Feb 16, 2005
    Insmed Provides Response to UK Patent Lawsuit

    Read more

  • Jan 7, 2005
    University of Rochester Awarded $6.5 Million to Study Efficacy OF rhIGF-I/rhIGFBP-3, SomatoKine, in the Treatment of Myotonic Dystrophy

    Read more

  • Jan 3, 2005
    Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome

    Read more

  • Dec 31, 2004
    Insmed Completes New Drug Application -NDA- for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome; Conference Call Scheduled for 11:00 am January 5, 2005

    Read more

  • Dec 30, 2004
    Insmed Incorporated Released the Following Statement in Response to Recent Actions by Tercica, Inc.

    Read more

  • Dec 21, 2004
    Insmed Incorporated Released the Following Statement in Response to a Press Release Made Yesterday by Tercica, Inc.

    Read more

  • Nov 9, 2004
    Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine

    Read more

  • Nov 8, 2004
    Insmed Raises Approximately $8.7 Million in Direct Placement of Common Stock

    Read more

  • Nov 8, 2004
    Insmed Incorporated Reports Financial Results for Third Quarter and First Nine-Months of 2004

    Read more

  • Oct 26, 2004
    Insmed to Present at Rodman and Renshaw Healthcare Conference October 28, 2004; Presentation to Be Webcast Live

    Read more

  • Oct 21, 2004
    Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories

    Read more

  • Oct 19, 2004
    Insmed Announces Initiation of Clinical Study of Small Molecule IGF-IR Tyrosine Kinase Inhibitor

    Read more

  • Sep 13, 2004
    Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European Society of Pediatric Endocrinology

    Read more

  • Sep 8, 2004
    Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Protein

    Read more

  • Aug 17, 2004
    Insmed Requests Halt of Trading of Its Common Stock on the Berlin-Bremen Stock Exchange; Company Also Initiates Short Selling Audit

    Read more

  • Jul 28, 2004
    Insmed Incorporated Reports Financial Results for Second Quarter and First Half of 2004

    Read more

  • Jul 21, 2004
    Insmed to Report Second Quarter Financial Results;Wednesday, July 28

    Read more

  • Jul 20, 2004
    Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months

    Read more

  • Jul 19, 2004
    Insmed Receives Authorization for Reimbursement for SomatoKine Named Patient Program from France and Italy; Newly Appointed Chief Business Officer Expands the Named Patient Program

    Read more

  • Jul 19, 2004
    Insmed Announces Two Independent Presentations at the National Cancer Institutes 12th Annual Meeting of SPORE

    Read more

  • May 13, 2004
    Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials

    Read more

  • May 11, 2004
    Insmed to Present at Rodman and Renshaw Healthcare Conference May 13, 2004; Presentation to Be Webcast Live

    Read more

  • May 5, 2004
    Insmed Incorporated Reports Financial Results for First Quarter of 2004

    Read more

  • Apr 29, 2004
    Insmed Incorporated to Webcast First Quarter Earnings Conference Call; Thursday, May 6, at 11:00 a.m. ET - 10:00 a.m. CT

    Read more

  • Apr 14, 2004
    Insmed Acquires Manufacturing Facility from Baxter International

    Read more

Show 5102550100 per page
  • «
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy ChoicesCookie Settings

ยฉ 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.